Safety, Tolerability, and Pharmacokinetics of Dapsone in Acne Vulgaris
| Status: | Completed |
|---|---|
| Conditions: | Acne, Acne, Dermatology |
| Therapuetic Areas: | Dermatology / Plastic Surgery |
| Healthy: | No |
| Age Range: | 16 - 35 |
| Updated: | 5/27/2013 |
| Start Date: | January 2013 |
| End Date: | August 2013 |
| Contact: | Allergan Inc. |
| Email: | clinicaltrials@allergan.com |
This study will evaluate the safety, tolerability, and pharmacokinetics (PK) of dapsone in
subjects with acne vulgaris following 28 days of dosing.
Inclusion Criteria:
- Diagnosis of acne vulgaris
- Willing to avoid excessive or prolonged exposure to ultraviolet light (e.g.,
sunlight, tanning beds) throughout the study
- If male, the subject must agree to shave the facial treatment area and agree to
maintain his routine shaving regimen for the duration of the study
- willing to avoid applying moisturizers, sunscreens, cosmetics (except eye and lip
makeup), and chemical peels throughout the study
Exclusion Criteria:
- Oral acne treatments within 6 months
We found this trial at
1
site
Click here to add this to my saved trials
